Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For suboptimal echocardiograms. Sold as Definity, Definity Rt. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Perflutren (sold as Definity, Definity Rt), first approved Jul 31, 2001, with 2 new uses approved and 0 published complete response letters.
First approved: Jul 31, 2001
Applications: 1
New uses approved: 2
Complete response letters: 0
Clinical Trials
44 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
